5:40 PM
 | 
Jun 13, 2014
 |  BC Extra  |  Company News

Celgene exercises early option to Agios' AG-221

Celgene Corp. (NASDAQ:CELG) exercised an option under a 2010 deal with Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to license exclusive, worldwide rights to develop and commercialize Agios' AG-221, an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The compound is...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >